PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Penumbra Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$322.41+1.55 (+0.48%)
Close on Oct 19, 2026
- Market cap
- $12.76B
- P/E (TTM)
- 79.2
- Dividend yield
- –
Penumbra Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | $947.92M | $815.48M | $677.34M | $511.14M | $437.78M | – | – | – | – | – | 67.5% | +16.2% |
| Embolization and Other | $455.75M | $379.14M | $381.18M | $336.00M | $309.82M | – | – | – | – | – | 32.5% | +20.2% |
| Vascular | – | – | – | $499.39M | $408.88M | $267.78M | $215.72M | $150.61M | $101.32M | $77.78M | – | – |
| Neuro | – | – | – | $347.74M | $338.71M | $292.63M | $331.69M | $294.33M | $232.45M | $185.53M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.09B | $902.07M | $757.15M | $591.72M | $527.79M | $400.27M | $355.22M | $290.72M | $219.17M | $176.10M | 77.8% | +21.0% |
| International | $311.90M | $292.55M | $301.37M | $255.42M | $219.80M | $160.14M | $192.18M | $154.22M | – | – | 22.2% | +6.6% |
| Japan | – | – | – | – | – | – | $42.52M | $41.81M | $33.79M | $30.28M | – | – |
| International | – | – | – | – | – | – | $149.66M | $112.42M | $80.80M | $56.93M | – | – |
From the segment and revenue-disaggregation notes of Penumbra's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.